4-octyl-3-(trifluoromethyl)aniline | 1088699-54-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-octyl-3-(trifluoromethyl)aniline
• CAS: 1088699-54-0
• 化学式: C₁₅H₂₂F₃N
• 分子量: 273.342
• InChiKey: HLGPPHZPFKMZAL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-octyl-3-(trifluoromethyl)aniline 在 氨 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 19.0h， 生成 1-(4-octyl-3-(trifluoromethyl)phenyl)thiourea
  参考文献：
  名称：

  WO2008/147557

  摘要：

  公开号：
• 作为产物：
  描述：

  2-溴-5-硝基三氟甲苯 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 palladium 10% on activated carbon 氢气 、 三乙胺 作用下， 以 1,4-二氧六环 、 乙醇 、 乙酸乙酯 为溶剂， 20.0~100.0 ℃ 、275.8 kPa 条件下， 反应 32.0h， 生成 4-octyl-3-(trifluoromethyl)aniline
  参考文献：
  名称：

  WO2008/147557

  摘要：

  公开号：

文献信息

• Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity
  申请人：Liu Cuixan

  公开号：US20090304605A1

  公开（公告）日：2009-12-10

  The invention provides amino-substituted aminothiazole compounds of Formula I and Formula II where A is a group of the formula: and the variables X, Y, R, and R 1 to R 7 are described herein. These compounds are prodrugs of compounds useful as inhibitors of viral replication. Compositions containing such compounds, and methods of treating viral infections with these compounds, as well as to processes and intermediates useful for preparing such compounds are also provided by the invention.

  该发明提供了公式I和公式II的氨基取代氨噻唑化合物，其中A是以下式的基团：变量X、Y、R和R1至R7如本文所述。这些化合物是可用作抑制病毒复制的化合物的前药。该发明还提供了含有这些化合物的组合物，以及使用这些化合物治疗病毒感染的方法，以及用于制备这些化合物的过程和中间体。
• Exploring amino acids derivatives as potent, selective, and direct agonists of sphingosine-1-phosphate receptor subtype-1
  作者：Ghotas Evindar、Hongfeng Deng、Sylvie G. Bernier、Elisabeth Doyle、Jeanine Lorusso、Barry A. Morgan、William F. Westlin

  DOI：10.1016/j.bmcl.2012.11.053

  日期：2013.1

  In the quest to discover a potent and selective class of direct agonists to the sphingosine-1-phosphate receptor, we explored the carboxylate functional group as a replacement to previously reported lead phosphates. This has led to the discovery of potent and selective direct agonists with moderate to substantial in vivo lymphopenia. The previously reported selectivity enhancing moiety (SEM) and selectivity enhancing orientation (SEO) in the phenylamide and phenylimidazole scaffolds were crucial to obtaining selectivity for S1P receptor subtype 1 over 3. (C) 2012 Elsevier Ltd. All rights reserved.
• SUBSTITUTED AMINOTHIAZOLE PRODRUGS OF COMPOUNDS WITH ANTI-HCV ACTIVITY
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：EP2297143A1

  公开（公告）日：2011-03-23
• HETEROARYL SUBSTITUTED THIAZOLES
  申请人：Wang Xiangzhu

  公开号：US20090041720A1

  公开（公告）日：2009-02-12

  The invention provides heteroaryl substituted thiazolo compounds of Formula I and II and pharmaceutically acceptable salts thereof. The variables A and R 3 to R 7 are defined herein. The invention also includes methods for preparing compounds and salts of Formula I and II. The present invention also includes pharmaceutical compositions containing heteroaryl substituted thiazolo compounds and methods for using heteroaryl substituted thiazolo compounds, including methods for using the compounds in the treatment of hepatitis C virus.
• US8106209B2
  申请人：——

  公开号：US8106209B2

  公开（公告）日：2012-01-31